Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma

Liver International

Volumn 33, Issue 6, 2013, Pages 950-957

  Cho, Ju Yeon ^a   Paik, Yong Han ^a   Lim, Ho Yeong ^a   Kim, Young Gon ^a   Lim, Hyo Keun ^a   Min, Yang Won ^a   Gwak, Geum Youn ^a   Choi, Moon Seok ^a   Lee, Joon Hyeok ^a   Koh, Kwang Cheol ^a   Paik, Seung Woon ^a   Yoo, Byung Chul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Diarrhoea; Hand foot syndrome; Hepatocellular carcinoma; Sorafenib

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD PUGH SCORE; DIARRHEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PREDICTIVE VALUE; RETROSPECTIVE STUDY; STOMATITIS; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DIARRHEA; DISEASE PROGRESSION; FEMALE; HAND-FOOT SYNDROME; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878903723     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12168     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
3. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
5. Carr BI, Carroll S, Muszbek N, Gondek K. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2010; 25: 1739-46.
6. Scandurra G, Aiello RA, Ali M, et al. Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-centre experience. Future Oncol 2012; 8: 609-15.
7. Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-300.
8. Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 2009; 7: 41.
9. Pinter M, Sieghart W, Hucke F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011; 34: 949-59.
10. Otsuka T, Eguchi Y, Kawazoe S, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 2012; 42: 879-86.
11. EASL-EORTC. Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
12. Lee JH, Park JY. Kim do Y., et al. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 2011; 31: 1144-9.
13. Estfan B, Byrne M, Kim R. Sorafenib in Advanced Hepatocellular Carcinoma: hypertension as a Potential Surrogate Marker for Efficacy. Am J Clin Oncol. 2012 doi: 10.1097/COC.0b013e3182468039 [Epub ahead of print].
14. Zhao Y, Yang M, Qi X, Han G, Fan D. Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma. Hepatology 2012; 56: 790-1.
15. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumour control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85-92.
16. Bettinger D, Schultheibeta M, Knuppel E, et al. Diarrhoea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology 2012; 56: 789-90.
17. Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590-6.
18. Baek KK, Kim JH, Uhm JE, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology 2011; 80: 167-74.
19. Choi JY. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea. Oncology 2011; 81(Suppl 1): 141-7.
20. Hollebecque A, Cattan S, Romano O, et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 34: 1193-201.
21. Chiu J, Tang YF, Yao TJ, et al. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety and survival benefits. Cancer 2012; 118: 5293-301.
22. Kim JE, Ryoo BY, Ryu MH, et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011; 68: 1285-90.
23. Sakar B, Ustuner Z, Karagol H, et al. Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis. Am J Clin Oncol 2004; 27: 489-93.
24. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274-83.
25. Song T, Zhang W, Wu Q, Kong D, Ma W. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol 2011; 23: 1233-8.
26. Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations because of multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158: 592-6.
27. Iijima M, Fukino K, Adachi M, et al. Sorafenib-associated hand-foot syndrome in Japanese patients. J Dermatol 2011; 38: 261-6.
28. Luo XN, Lu LG, Shao PJ, et al. Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 2012; 92: 889-93.
29. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913-21.
30. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8(Suppl 1): S7-14.